Firmagon

Phase 2Small molecule

Ferring

Firmagon is one of 107 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Prostate CancerActive, not recruiting

Prostate CarcinomaPreclinical

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Prostate CancerPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Firmagon

Ferring

Phase 2

1 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2/3Recruiting

Prostate Cancer

NCT06282588

Clinical

Trials by Indication[1]

Adenocarcinoma1 trial

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

Completed·CCentre Leon Berard·Phase 2·NCT04391556·57 enrolled

Prostate Cancer1 trial

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting·CCancer Research Antwerp·Phase 2/3·NCT06282588·493 enrolled

Prostate Carcinoma1 trial

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

Completed· Ferring logo

Ferring··NCT01861236·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Firmagon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Firmagon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Firmagon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Ferring

Firmagon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Adenocarcinoma1 trial

Prostate Cancer1 trial

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News